Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Prosonix Appoints Cécile Miles as Chief Business Officer

Published: Tuesday, February 12, 2013
Last Updated: Tuesday, February 12, 2013
Bookmark and Share
Appointment significantly strengthens corporate and commercial development experience in the generics and speciality pharmaceutical markets.

Prosonix has appointed Cécile Miles as Chief Business Officer. In this newly created role, Ms Miles will help develop and drive Prosonix’ business development and commercial strategy, which is designed to capitalize on the potential value of its portfolio of directly substitutable generic and novel inhaled respiratory candidates.

Ms Miles has extensive business development and commercial experience within the pharmaceutical, biotechnology and generics sector, and strong global networks.

She joins Prosonix from the Watson group (now known as Actavis, Inc.), the world's third-largest generics company, where she was Commercial Director EU.

Before Watson, Ms Miles was Executive Director of Commercial Development at Ark Therapeutics, Executive Director of Global Business Development at Pliva, and Head of the European Division at Ranbaxy Laboratories Ltd. She also spent several years in a variety of commercial roles at Fisons plc.

Commenting on the appointment, David Hipkiss, Prosonix’ CEO, said: “Cécile is a highly experienced business development professional and brings excellent complementary skills and understanding of the generics and speciality pharmaceutical markets to Prosonix. She will play a key role in driving Prosonix’ business development strategy over the coming years as we explore opportunities to capture the full potential value of our portfolio of directly substitutable inhaled generics and novel combination respiratory candidates. 2013 is expected to be an exciting year as we prepare to submit our application for marketing approval with European regulators for PSX1001, to initiate first clinical trials of PSX1002, and to advance the development of our novel PSX2000 combination candidates to address a range of respiratory diseases.”

Cécile Miles added: “I am very excited to be joining the Prosonix team at this crucial juncture in the Company’s development. Prosonix is approaching some important development milestones in 2013 with the lead candidates in its respiratory medicine pipeline. In addition, the Company is receiving great interest from third parties about the potential of its platform both to develop new medicines and to optimize those that are currently used in the treatment of respiratory diseases.”


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Prosonix Reports Positive Top-line Results from its Phase 2 Clinical Study with PSX1002
First clinical data from PSX1002, a novel, orally inhaled, drug-only, pMDI suspension formulation of glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA).
Friday, January 31, 2014
Final Patient Completes Prosonix’ Phase 2 Clinical Study with PSX1002
PSX1002 is a novel, orally inhaled, drug-only, pMDI suspension formulation of glycopyrronium bromide, a long-acting muscarinic antagonist (LAMA).
Monday, August 19, 2013
Prosonix Initiates Phase 2 Clinical Study with PSX1002 in COPD Patients
First patients dosed with PSX1002, an orally inhaled, novel drug-only formulation of glycopyrronium bromide designed using Prosonix’ particle engineering platform.
Thursday, May 23, 2013
Prosonix Elects Dr Ken Cunningham as Non-executive Chairman
Dr Cunningham replaces Dr Jim Philips, who is retiring from the Board of Directors.
Wednesday, December 05, 2012
Prosonix Enters Collaboration with Imperial College London
Collaborative research agreement to accelerate development of engineered combination respiratory medicines.
Thursday, July 05, 2012
Prosonix Extends Series B Financing Round to £17.1M
Gimv joins syndicate of experienced life science investors - Karl Nägler joins Board as Non-executive Director.
Tuesday, May 22, 2012
Prosonix to Present at RDD 2012 and ATS 2012 International Conference
Prosonix will present a poster entitled ‘Engineered Combination Respiratory Medicines for Localized Drug Delivery’ at RDD.
Wednesday, May 09, 2012
Prosonix Demonstrates Improved Delivery and Co-localization of Respiratory Medicines
New review published in European Respiratory Disease(ERD).
Thursday, May 03, 2012
Prosonix Appoints Dr Geoff Down as Chief Medical Officer
Dr Down will oversee the clinical development of Prosonix's product pipeline.
Monday, February 06, 2012
Prosonix Appoints Rob Crocker as its First Head of Regulatory Affairs
Mr Crocker will be responsible for defining and implementing the regulatory strategy to underpin the development of Prosonix’ emerging product pipeline.
Friday, January 20, 2012
Prosonix Appoints New Scientific Advisory Board
New SAB comprises distinguished experts in respiratory disease, and in clinical and regulatory aspects of respiratory drug development.
Friday, October 28, 2011
Scientific News
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
New Diabetes Drug has Unexpected Side Effect
A type of drug used to treat diabetes may reduce the risk of developing Parkinson’s disease, according to new research.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Cannabis May Be Used to Treat Fractures
TAU researcher finds non-psychotropic compound in marijuana can help heal bone fissures.
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Creating More Potent Vaccines
Yale researchers uncovered a new role for a type of immune cell, known as regulatory T cells, in promoting long-term immunity.
Potential Therapeutic for Blinding Eye Disease
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Potential New Class of Cancer Drugs
Scientists have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Global Search for Next Antibiotic
University of Queensland researchers have launched a global search to discover antibiotics capable of combating superbug bacteria that are resistant to current antibiotics.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!